Deals this week: Teva Pharma, Boston Children’s Hospital, MedImmune
Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers in Israel.
According to the agreement, Teva Pharma will be responsible for marketing and distribution of the inhaler in Israel.
The agreement enables the two partners to introduce medical cannabis for pain management.
Boston Children’s Hospital and GE Health Care have entered an agreement to develop advanced digital solutions to detect paediatric brain disorders.
Pursuant to the same agreement, the two partners will jointly work on development and commercialisation of diagnosis and treatments for childhood brain diseases.
MedImmune and Abpro Corporation have entered a collaborative agreement to a bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor.
According to the agreement, Abpro's subsidary AbMed will be responsible for global development and commercialisation of the novel antibody candidate and MedImmune will receive payments during the drugs development, regulatory and sales milestone and additional royalties.
The agreement enables the two partners to explore different potential areas for bispecific antibody.
Catalent plans to raise $400m through the private placement of senior unsecured notes due 2024. The offer will be subscribed to by institutional buyers.
The company plans to invest the funds to acquire Accucaps Industries, to repay the debts and for certain general corporate purposes.
Innovent Biologics has raised $260m in a series D venture financing round led by Future Industries Investment Fund (FIIF) and co-led by China Life Insurance and other blue chip investors.
The company plans to use the funds to further advance the development of product pipeline and expand its manufacturing capacity.
Image: Teva Pharma Industries and Syqe Medical have entered an agreement to market medical cannabis inhalers.